This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sequist, L. V. Articles by Haber, D. A. Search for Related Content PubMed PubMed Citation Articles by Sequist, L. V. Articles by Haber, D. A. Social Bookmarking                            What's this?

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Lecia V. Sequist, Daphne W. Bell, Thomas J. Lynch, Daniel A. Haber

From the Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Address reprint requests to Daniel Haber, MD, PhD, MGH Cancer Center, CNY-7, Building 149, 13th St, Charlestown, MA 02129; e-mail: Haber{at}helix.mgh.harvard.edu

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the most important targets for drug development in oncology. Monoclonal antibodies targeting the external domain of EGFR have been shown to have clinical benefit in colorectal and head and neck cancer when combined with chemotherapy and/or radiation. Small molecules that inhibit the tyrosine kinase (TK) domain of EGFR have become critical new weapons in the treatment of non–small-cell lung cancer (NSCLC). The discovery that mutations in the TK domain are associated with dramatic and sustained responses to EGFR TK inhibitors (TKIs) has allowed the design of trials to test these agents as potential first-line therapies and has provided a fascinating window into the future of genotype-directed targeted therapy. Recent advances in understanding the biologic basis of acquired resistance to these agents have great potential to improve the clinical effectiveness of this class of drugs. This review summarizes the biology of EGFR in NSCLC, the clinical and molecular predictors of benefit from treatment with EGFR TKIs, the use of patient-specific molecular profiling, and future directions of clinical and basic scientific research.

L.V.S. and D.W.B. contributed equally to this article.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Peled, K. Yoshida, M. W. Wynes, and F. R. Hirsch Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 137 - 144. [Abstract] [PDF]

				P. P. Zarrinkar, R. N. Gunawardane, M. D. Cramer, M. F. Gardner, D. Brigham, B. Belli, M. W. Karaman, K. W. Pratz, G. Pallares, Q. Chao, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood, October 1, 2009; 114(14): 2984 - 2992. [Abstract] [Full Text] [PDF]

				C. M. Rudin, C. L. Hann, J. Laterra, R. L. Yauch, C. A. Callahan, L. Fu, T. Holcomb, J. Stinson, S. E. Gould, B. Coleman, et al. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449 N. Engl. J. Med., September 17, 2009; 361(12): 1173 - 1178. [Abstract] [Full Text] [PDF]

				S. J. Mandrekar and D. J. Sargent Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges J. Clin. Oncol., August 20, 2009; 27(24): 4027 - 4034. [Abstract] [Full Text] [PDF]

				S. A. Milligan, P. Burke, D. T. Coleman, R. L. Bigelow, J. J. Steffan, J. L. Carroll, B. J. Williams, and J. A. Cardelli The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer Cells Clin. Cancer Res., August 1, 2009; 15(15): 4885 - 4894. [Abstract] [Full Text] [PDF]

				T. SHUKUYA, T. TAKAHASHI, A. TAMIYA, A. ONO, S. IGAWA, Y. NAKAMURA, A. TSUYA, H. MURAKAMI, T. NAITO, K. KAIRA, et al. Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib Anticancer Res, July 1, 2009; 29(7): 2747 - 2751. [Abstract] [Full Text] [PDF]

				L. V. Sequist, J. A. Engelman, and T. J. Lynch Toward Noninvasive Genomic Screening of Lung Cancer Patients J. Clin. Oncol., June 1, 2009; 27(16): 2589 - 2591. [Full Text] [PDF]

				S. D. RICE, J. E. BUSH, and S. L. BROWER Assessment of Erlotinib in Chemoresponse Assay Anticancer Res, June 1, 2009; 29(6): 1993 - 1997. [Abstract] [Full Text] [PDF]

				N. A. Pennell and T. J. Lynch Jr. Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC Oncologist, April 1, 2009; 14(4): 399 - 411. [Abstract] [Full Text] [PDF]

				A. N. Hughes, M. E.R. O'Brien, W. J. Petty, J. B. Chick, E. Rankin, P. J. Woll, D. Dunlop, M. Nicolson, R. Boinpally, J. Wolf, et al. Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers J. Clin. Oncol., March 10, 2009; 27(8): 1220 - 1226. [Abstract] [Full Text] [PDF]

				P. Laurent-Puig, A. Lievre, and H. Blons Mutations and Response to Epidermal Growth Factor Receptor Inhibitors Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139. [Abstract] [Full Text] [PDF]

				B. Zhao, L. H. Schwartz, and S. M. Larson Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers J. Nucl. Med., February 1, 2009; 50(2): 239 - 249. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti, P. Ceppi, S. Novello, and M. Papotti Chemotherapy Treatment Decisions in Advanced Non-small Cell Lung Cancer Based on Histology ASCO Educational Book, January 1, 2009; 2009(1): 431 - 435. [Abstract] [Full Text] [PDF]

				G. J. Riely and M. Ladanyi KRAS Mutations: An Old Oncogene Becomes a New Predictive Biomarker J. Mol. Diagn., November 1, 2008; 10(6): 493 - 495. [Abstract] [Full Text] [PDF]

				T. M. Chin, M. P. Quinlan, A. Singh, L. V. Sequist, T. J. Lynch, D. A. Haber, S. V. Sharma, and J. Settleman Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment Clin. Cancer Res., November 1, 2008; 14(21): 6867 - 6876. [Abstract] [Full Text] [PDF]

				D. B. Costa, K.-S. H. Nguyen, B. C. Cho, L. V. Sequist, D. M. Jackman, G. J. Riely, B. Y. Yeap, B. Halmos, J. H. Kim, P. A. Janne, et al. Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib Clin. Cancer Res., November 1, 2008; 14(21): 7060 - 7067. [Abstract] [Full Text] [PDF]

				M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]

				F. R. Hirsch, M. Varella-Garcia, R. Dziadziuszko, Y. Xiao, S. Gajapathy, M. Skokan, M. Lin, V. O'Neill, and P. A. Bunn Jr. Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6317 - 6323. [Abstract] [Full Text] [PDF]

				R. S. Herbst, J. V. Heymach, and S. M. Lippman Lung Cancer N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380. [Full Text] [PDF]

				A. M. Oza, E. A. Eisenhauer, L. Elit, J.-C. Cutz, A. Sakurada, M. S. Tsao, P. J. Hoskins, J. Biagi, P. Ghatage, J. Mazurka, et al. Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 J. Clin. Oncol., September 10, 2008; 26(26): 4319 - 4325. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance? Oncologist, September 1, 2008; 13(9): 933 - 944. [Abstract] [Full Text] [PDF]

				H.-S. Seo, D. D. Liu, B. N. Bekele, M.-K. Kim, K. Pisters, S. M. Lippman, I. I. Wistuba, and J. S. Koo Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Non-Small Cell Lung Cancer Cancer Res., August 1, 2008; 68(15): 6065 - 6073. [Abstract] [Full Text] [PDF]

				T. Fukui, Y. Ohe, K. Tsuta, K. Furuta, H. Sakamoto, T. Takano, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, et al. Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2008; 14(15): 4751 - 4757. [Abstract] [Full Text] [PDF]

				L. V. Sequist, J. E. Settleman, J. B. Ackman, and A. J. Iafrate Case 23-2008 -- A 26-Year-Old Man with Back Pain and a Mass in the Lung N. Engl. J. Med., July 24, 2008; 359(4): 405 - 414. [Full Text] [PDF]

				S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells N. Engl. J. Med., July 24, 2008; 359(4): 366 - 377. [Abstract] [Full Text] [PDF]

				V. Pitini, C. Arrigo, and G. Altavilla Erlotinib in a Patient With Acute Myelogenous Leukemia and Concomitant Non-Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2008; 26(21): 3645 - 3646. [Full Text] [PDF]

				R. P. Regala, E. A. Thompson, and A. P. Fields Atypical Protein Kinase C{iota} Expression and Aurothiomalate Sensitivity in Human Lung Cancer Cells Cancer Res., July 15, 2008; 68(14): 5888 - 5895. [Abstract] [Full Text] [PDF]

				L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Janne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, et al. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol., May 20, 2008; 26(15): 2442 - 2449. [Abstract] [Full Text] [PDF]

				U. McDermott, A. J. Iafrate, N. S. Gray, T. Shioda, M. Classon, S. Maheswaran, W. Zhou, H. G. Choi, S. L. Smith, L. Dowell, et al. Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors Cancer Res., May 1, 2008; 68(9): 3389 - 3395. [Abstract] [Full Text] [PDF]

				A. R. Li, D. Chitale, G. J. Riely, W. Pao, V. A. Miller, M. F. Zakowski, V. Rusch, M. G. Kris, and M. Ladanyi EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression J. Mol. Diagn., May 1, 2008; 10(3): 242 - 248. [Abstract] [Full Text] [PDF]

				S. D Baker Pharmacokinetic Considerations for Molecularly Targeted Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 705 - 709. [Abstract] [Full Text] [PDF]

				F. Ciardiello and G. Tortora EGFR Antagonists in Cancer Treatment N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174. [Full Text] [PDF]

				A. Dowlati and P. Fu Is Response Rate Relevant to the Phase II Trial Design of Targeted Agents? J. Clin. Oncol., March 10, 2008; 26(8): 1204 - 1205. [Full Text] [PDF]

				S. Aggarwal, S.-W. Kim, S.-H. Ryu, W.-C. Chung, and J. S. Koo Growth Suppression of Lung Cancer Cells by Targeting Cyclic AMP Response Element-Binding Protein Cancer Res., February 15, 2008; 68(4): 981 - 988. [Abstract] [Full Text] [PDF]

				D. B. Costa and S. Kobayashi Response of Intracranial Metastases to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: It May All Depend on EGFR Mutations J. Clin. Oncol., February 1, 2008; 26(4): 686 - 686. [Full Text] [PDF]

				U. McDermott, S. V. Sharma, L. Dowell, P. Greninger, C. Montagut, J. Lamb, H. Archibald, R. Raudales, A. Tam, D. Lee, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling PNAS, December 11, 2007; 104(50): 19936 - 19941. [Abstract] [Full Text] [PDF]

				W. Liu, X. Wu, W. Zhang, R. C. Montenegro, D. L. Fackenthal, J. A. Spitz, L. M. Huff, F. Innocenti, S. Das, E. H. Cook, Jr., et al. Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines Clin. Cancer Res., November 15, 2007; 13(22): 6788 - 6795. [Abstract] [Full Text] [PDF]

				C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood, October 1, 2007; 110(7): 2674 - 2684. [Abstract] [Full Text] [PDF]

				O. Riesterer, L. Milas, and K. K. Ang Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy J. Clin. Oncol., September 10, 2007; 25(26): 4075 - 4083. [Abstract] [Full Text] [PDF]

				B. E. Johnson, D. Jackman, and P. A. Janne Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4628s - 4631s. [Abstract] [Full Text] [PDF]

				T. J. Liang Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 -- Is Less More? N. Engl. J. Med., July 12, 2007; 357(2): 176 - 178. [Full Text] [PDF]

				K. E. Finberg, L. V. Sequist, V. A. Joshi, A. Muzikansky, J. M. Miller, M. Han, J. Beheshti, L. R. Chirieac, E. J. Mark, and A. J. Iafrate Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features J. Mol. Diagn., July 1, 2007; 9(3): 320 - 326. [Abstract] [Full Text] [PDF]

				L. V. Sequist Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Oncologist, March 1, 2007; 12(3): 325 - 330. [Abstract] [Full Text] [PDF]